Search clinical trials for: LEO 43204 gel 0.018%

Total 80 results

LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Biological Effects of LEO 43204 in Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Peplin

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Korea University
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

Actinic Keratosis

Korea, Republic of
University of California, San Francisco

Completed

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

Actinic Keratosis

United States
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Italy
Skin Laser & Surgery Specialists
LEO Pharma

Completed

Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

Actinic Keratosis | Photo-aged Skin
Peplin

Completed

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy

United States
LEO Pharma

Completed

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Actinic Keratosis

United States
LEO Pharma

Completed

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Actinic Keratosis

Canada, Germany, Australia, France, United Kingdom
LEO Pharma

Completed

PMS to Evaluate the Safety and Efficacy of Picato® Gel

Actinic Keratosis

Korea, Republic of
Universidade Federal do Para

Completed

Whitening Efficacy and Tooth Sensitivity of Different Concentrations of Hydrogen Peroxide Photoactivated With Violet or Blue LEDs

Color | Bleaching Sensitivity

Brazil
Fondazione Don Carlo Gnocchi Onlus

Completed

Efficacy of End-Effector Robot-Assisted Gait Training Combined With Robotic Balance Training in Subacute Stroke Patients

Stroke

Italy
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

Connective Tissue Diseases | Skin Tissue Diseases

Germany
Nutravalia
Slb Pharma

Completed

Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers

Overweight and Obesity

France
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

United States
LEO Pharma
CMIC Co, Ltd. Japan

Completed

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

Psoriasis Vulgaris

United States, Canada, United Kingdom, Germany, Romania, France, Poland
PPM Services S.A.

Terminated

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC (SEGMENT)

Ulcerative Colitis

United States, Hungary, Slovakia, Italy, Ukraine, Bulgaria, Poland, Latvia, Canada, France
Örebro University, Sweden
Uppsala University; State University of New York - Downstate Medical Center; Dalarna... and other collaborators

Completed

Let's Get Organized Feasibility Study

Neurodevelopmental Disorders | Mental Disorder
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

Canada, United Kingdom, France
LEO Pharma

Completed

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

Skin and Connective Tissue Diseases

Japan
Mayo Clinic
Actelion

Completed

Valchlor in the Treatment of Lichen Planopilaris

Lichen Planopilaris

United States
Horus Pharma

Unknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Dry Eye
University of Copenhagen

Completed

Neurogenic Mechanisms in Burning Mouth Syndrome (BMS17)

Burning Mouth Syndrome

Denmark
Universita di Verona

Unknown

Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis (GE-O-VR)

Multiple Sclerosis

Italy
Bausch & Lomb Incorporated

Completed

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Pain | Ocular Inflammation | Cataract

United States
LEO Pharma

Completed

Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
Cytomedix
CTI Clinical Trial and Consulting Services

Terminated

The AutoloGel™ Post-Market Surveillance (TAPS) Program (TAPS)

Diabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg Ulcers

United States
Bausch & Lomb Incorporated

Completed

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

Healthy

United States
Örebro University, Sweden
Uppsala University; State University of New York - Downstate Medical Center; Dalarna... and other collaborators

Completed

"Let's Get Organized" in Adult Psychiatric/Habilitation Care

Neurodevelopmental Disorders | Mental Disorder

Sweden
Bausch & Lomb Incorporated

Completed

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Pharmacokinetics

United States
Medical University of Vienna

Completed

Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy (BCM_Volunteer)

Fluid Shifts | Body Fluid Compartments

Austria
National Institute of Allergy and Infectious Diseases...
GeoVax, Inc.

Completed

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

HIV Infections

United States
Thomas Jefferson University
Actelion

Unknown

Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides

Mycosis Fungoides | Cutaneous T-cell Lymphoma
National Institute of Allergy and Infectious Diseases...

Withdrawn

Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

HIV Infections
Bausch Health Americas, Inc.

Completed

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

Eye Pain

United States

3

Subscribe